NCT02833610 2026-02-18
A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
Massachusetts General Hospital
Phase 2 Completed
Clinical Trials
32 trialsNCT03839459 2026-01-28
Denosumab for Smoldering Multiple Myeloma
University of Rochester
Phase 2 Completed
NCT02051218 2025-12-30
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Swiss Cancer Institute
Phase 3 Active not recruiting
NCT04549207 2025-11-28
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
Ottawa Hospital Research Institute
Phase 4 Active not recruiting
NCT04067726 2025-10-16
TRIDENT
Washington University School of Medicine
Phase 2 Active not recruiting
NCT06513624 2025-07-25
ETC-159-02
National University Hospital, Singapore
Phase 1 Recruiting
NCT07043608 2025-07-02
ZAMBONI
University of California, San Francisco
Phase 2 Not yet recruiting
NCT04711109 2025-04-02
BRCA-P
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT03792763 2025-02-11
DEFENCE
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT06749886 2024-12-27
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT03629717 2024-10-16
RANKL Inhibition and Breast Tissue Biomarkers
Washington University School of Medicine
Phase EARLY_PHASE1 Completed
NCT03620019 2024-08-12
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03401060 2024-05-03
DenosuMast
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT03324932 2023-10-06
Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer
Kyoto Prefectural University of Medicine
Phase 3 Active not recruiting
NCT03280667 2023-03-29
KEYPAD
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT03161756 2022-04-07
CHARLI
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Unknown
NCT03732495 2022-03-29
LENVOS
Centre Leon Berard
Phase 2 Unknown
NCT03520231 2021-11-23
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
University Health Network, Toronto
Phase 2 Completed
NCT03408652 2021-10-22
MOSCAR
Centre Leon Berard
Phase 3 Terminated
NCT02366130 2021-10-07
Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03027557 2021-05-25
DENOCINA
Aalborg University Hospital
Phase 3 Completed
NCT01624766 2021-02-25
Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02682693 2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2 Completed
NCT01545648 2020-01-02
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
University of California, San Francisco
Phase 2 Terminated
NCT01952054 2019-11-22
Denosumab for Breast Cancer With Bone Mets
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02758132 2019-11-08
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
University of Hawaii
Phase 2 Terminated
NCT03605199 2019-08-26
Denosumab in Subjects With Giant Cell Rich Tumors of Bone
Leiden University Medical Center
Phase 2 Unknown
NCT03811509 2019-01-28
B-ABLE
Parc de Salut Mar
Phase 4 Unknown
NCT01864798 2018-11-27
D-Beyond
Jules Bordet Institute
Phase 2 Terminated
NCT03070002 2018-11-20
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
Northwestern University
Phase 2 Terminated
NCT03415477 2018-01-30
Deno-ABC
Peking University People's Hospital
Phase 1/2 Completed
NCT03259152 2017-08-24
D-Gct
Hebei Medical University Third Hospital
Phase 3 Unknown